{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:24:57Z","timestamp":1793294697952,"version":"4.5.0"},"reference-count":21,"publisher":"Massachusetts Medical Society","issue":"2","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100011112","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,7,8]]},"DOI":"10.1056\/nejmoa2102383","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T10:08:27Z","timestamp":1619172507000},"page":"142-152","source":"Crossref","is-referenced-by-count":402,"title":["Bimekizumab versus Secukinumab in Plaque Psoriasis"],"prefix":"10.1056","volume":"385","author":[{"given":"Kristian","family":"Reich","sequence":"first","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Cuyper","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Vanvoorden","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Madden","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cioffi","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Peterson","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"From the Center for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (K.R.); the Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, United Kingdom (R.B.W.); the Icahn School of Medicine at Mount Sinai, New York (M.L.); the SKiN Centre for Dermatology, Probity Medical Research, Peterborough, and Queen\u2019s University, Kingston, ON (M.G.), and Dalhousie University, Halifax, NS (R.G.L.) \u2014 all in Canada; Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell \u2014 both in Connecticut (B.S.); Paul Sabatier University, Toulouse, France (C.P.); UCB Pharma, Brussels (D.D.C., V.V.); UCB Pharma, Raleigh, NC (C.M., C.C., L.P.); and the Oregon Medical Research Center, Portland (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03465.x"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2799"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.038"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"e_1_3_5_12_2","first-page":"60","article-title":"Cosentyx (secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis.","volume":"9","author":"Fala L","year":"2016","unstructured":"Fala L. Cosentyx (secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis. Am Health Drug Benefits 2016;9(Special Feature):60-63.27668046","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1224658"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15655"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.105"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_3_5_19_2","first-page":"29","article-title":"Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.","volume":"9","author":"Chiricozzi A","year":"2019","unstructured":"Chiricozzi A, De Simone C, Fossati B, Peris K. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl) 2019;9:29-35.31214486","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500909"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329511"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-2-1"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2102383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:33:16Z","timestamp":1749670396000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2102383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,7,8]]}},"alternative-id":["10.1056\/NEJMoa2102383"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2102383","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}